Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site.

SARS-CoV-2 binding site coronavirus disease 2019 (COVID-19) inhibitors molecular docking molecular dynamics spike glycoprotein trimer cavity variability

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
14 May 2020
Historique:
received: 22 04 2020
revised: 08 05 2020
accepted: 12 05 2020
entrez: 20 5 2020
pubmed: 20 5 2020
medline: 20 5 2020
Statut: epublish

Résumé

An important stage in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) life cycle is the binding of the spike (S) protein to the angiotensin converting enzyme-2 (ACE2) host cell receptor. Therefore, to explore conserved features in spike protein dynamics and to identify potentially novel regions for drugging, we measured spike protein variability derived from 791 viral genomes and studied its properties by molecular dynamics (MD) simulation. The findings indicated that S2 subunit (heptad-repeat 1 (HR1), central helix (CH), and connector domain (CD) domains) showed low variability, low fluctuations in MD, and displayed a trimer cavity. By contrast, the receptor binding domain (RBD) domain, which is typically targeted in drug discovery programs, exhibits more sequence variability and flexibility. Interpretations from MD simulations suggest that the monomer form of spike protein is in constant motion showing transitions between an "up" and "down" state. In addition, the trimer cavity may function as a "bouncing spring" that may facilitate the homotrimer spike protein interactions with the ACE2 receptor. The feasibility of the trimer cavity as a potential drug target was examined by structure based virtual screening. Several hits were identified that have already been validated or suggested to inhibit the SARS-CoV-2 virus in published cell models. In particular, the data suggest an action mechanism for molecules including Chitosan and macrolides such as the mTOR (mammalian target of Rapamycin) pathway inhibitor Rapamycin. These findings identify a novel small molecule binding-site formed by the spike protein oligomer, that might assist in future drug discovery programs aimed at targeting the coronavirus (CoV) family of viruses.

Identifiants

pubmed: 32422996
pii: jcm9051473
doi: 10.3390/jcm9051473
pmc: PMC7290299
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Medical Research Council
ID : MR/P011349/1
Pays : United Kingdom
Organisme : Fundacja na rzecz Nauki Polskiej
ID : MAB/3/2017

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Références

Sci Adv. 2020 Feb 07;6(6):eaav7416
pubmed: 32083171
Cell Res. 2020 Apr;30(4):343-355
pubmed: 32231345
Aging (Albany NY). 2020 Mar 31;12(8):6492-6510
pubmed: 32229705
Expert Opin Investig Drugs. 2015;24(11):1409-18
pubmed: 26289790
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99
pubmed: 25487801
J Control Release. 2005 Apr 18;103(3):643-53
pubmed: 15820411
Cancer Res. 2009 Sep 1;69(17):6906-14
pubmed: 19671798
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Parasit Vectors. 2013 Mar 25;6:80
pubmed: 23531322
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Clin Microbiol Rev. 2015 Apr;28(2):465-522
pubmed: 25810418
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Cell Res. 2017 Jan;27(1):119-129
pubmed: 28008928
J Med Virol. 2020 Jun;92(6):595-601
pubmed: 32100877
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Clin Microbiol Rev. 2007 Oct;20(4):660-94
pubmed: 17934078
Int J Mol Sci. 2019 Nov 11;20(22):
pubmed: 31718065
ACS Cent Sci. 2020 Mar 25;6(3):315-331
pubmed: 32226821
Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18
pubmed: 32134278
J Clin Microbiol. 2006 Jun;44(6):2063-71
pubmed: 16757599
Front Pharmacol. 2020 Oct 09;11:585408
pubmed: 33162891
Bioinformatics. 2013 Apr 1;29(7):845-54
pubmed: 23407358
Chin Med J (Engl). 2020 May 5;133(9):1051-1056
pubmed: 32149769
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Trends Genet. 2000 Jun;16(6):276-7
pubmed: 10827456
J Antimicrob Chemother. 2004 Jan;53(1):4-9
pubmed: 14657084
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
PLoS One. 2016 Jun 01;11(6):e0156552
pubmed: 27249425
Nucleic Acids Res. 2011 Jan;39(Database issue):D392-401
pubmed: 21036868
Antiviral Res. 2013 Feb;97(2):112-21
pubmed: 23201315
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Int J Biol Sci. 2020 Mar 15;16(10):1718-1723
pubmed: 32226289
Viruses. 2019 Apr 04;11(4):
pubmed: 30987343
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Nat Microbiol. 2016 Feb 22;1:16004
pubmed: 27572168
Cell Discov. 2020 Mar 16;6:14
pubmed: 32194980
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11157-11162
pubmed: 29073020
J Biol Chem. 2020 Apr 10;295(15):4773-4779
pubmed: 32094225
Science. 2012 Oct 12;338(6104):221
pubmed: 22923433
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Viruses. 2020 Apr 10;12(4):
pubmed: 32290077
Int J Oncol. 2012 Aug;41(2):425-32
pubmed: 22614157
Methods Mol Biol. 2013;993:1-12
pubmed: 23568460
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
J Virol. 2005 Jan;79(2):884-95
pubmed: 15613317
Curr Opin Investig Drugs. 2010 Aug;11(8):951-63
pubmed: 20721837
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32244998
J Virol. 1990 Nov;64(11):5367-75
pubmed: 2170676
Sci Rep. 2019 Jun 18;9(1):8707
pubmed: 31213647
Nat Commun. 2017 Apr 10;8:15092
pubmed: 28393837
Nat Rev Drug Discov. 2004 Nov;3(11):935-49
pubmed: 15520816
Trends Microbiol. 2013 Oct;21(10):544-55
pubmed: 23770275
J Chem Theory Comput. 2010 Feb 9;6(2):459-66
pubmed: 26617301
J Chem Phys. 2007 Jan 7;126(1):014101
pubmed: 17212484
Soc Sci Med. 2006 Dec;63(12):3113-23
pubmed: 16978751
J Virol. 2003 Aug;77(16):8801-11
pubmed: 12885899
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Medicine (Baltimore). 2020 Nov 25;99(48):e23357
pubmed: 33235105
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Lancet. 2003 Apr 19;361(9366):1319-25
pubmed: 12711465
Biochem Biophys Res Commun. 2020 Jun 30;527(3):702-708
pubmed: 32410735

Auteurs

Umesh Kalathiya (U)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.

Monikaben Padariya (M)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.

Marcos Mayordomo (M)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.

Małgorzata Lisowska (M)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.

Judith Nicholson (J)

Sharp Life Science (EU) Limited, Oxford Science Park, Edmund Halley Rd, Oxford OX4 4GB, UK.

Ashita Singh (A)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.

Maciej Baginski (M)

Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233 Gdansk, Poland.

Robin Fahraeus (R)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.

Neil Carragher (N)

Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland EH4 2XR, UK.

Kathryn Ball (K)

Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland EH4 2XR, UK.

Juergen Haas (J)

Department of Infectious Disease, Edinburgh, Scotland EH4 2XR, UK.

Alison Daniels (A)

Department of Infectious Disease, Edinburgh, Scotland EH4 2XR, UK.

Ted R Hupp (TR)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.
Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland EH4 2XR, UK.

Javier Antonio Alfaro (JA)

International Centre for Cancer Vaccine Science, University of Gdansk, Wita Stwosza 63, 80-308 Gdansk, Poland.
Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland EH4 2XR, UK.

Classifications MeSH